Status:
UNKNOWN
Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
Ovarian cancer is the first mortality rate of gynecologic malignancies. The incidence of ovarian cancer increased in recent 10 years. Ovarian cancer indeed is a disease that should be respected, howev...
Detailed Description
Malignancy is the first cause of death in Taiwan. There are around 30,000 people died due to malignancy every year. Ovarian cancer is the first mortality rate of gynecologic malignancies. The incidenc...
Eligibility Criteria
Inclusion
- \- ovarian cancer
Exclusion
- \-
Key Trial Info
Start Date :
January 1 2003
Trial Type :
OBSERVATIONAL
End Date :
December 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00155896
Start Date
January 1 2003
End Date
December 1 2008
Last Update
September 12 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan